

Consensus or Controversy? Clinical Investigator Perspectives on the Current and Future Management of Hepatocellular Carcinoma and Pancreatic Cancer (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. What was reported with regard to progression-free survival (PFS) and overall survival (OS) in the CELESTIAL trial evaluating cabozantinib versus placebo for patients with previously treated advanced hepatocellular carcinoma (HCC)?**
  - Significant improvement in only OS with cabozantinib
  - Significant improvement in only PFS with cabozantinib
  - Significant improvement in both PFS and OS with cabozantinib
- 2. What was the 5-year OS outcome with gemcitabine/*nab* paclitaxel in the Phase III APACT trial comparing that combination to gemcitabine alone for surgically resected pancreatic cancer?**
  - Improvement
  - No improvement
- 3. The POLO trial, investigating maintenance therapy with olaparib versus placebo for patients with metastatic pancreatic cancer who had a germline BRCA mutation, demonstrated which of the following outcomes with olaparib?**
  - Statistically significant improvement in OS only
  - Statistically significant improvement in PFS only
  - Statistically significant improvement in both PFS and OS
- 4. Pemigatinib was approved by the FDA for patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma who have which of the following alterations?**
  - BRCA1/2 mutation
  - ATM mutation
  - FGFR2 fusion or rearrangement
- 5. Results of the Phase III ClarIDHy study demonstrated improvement in PFS with ivosidenib compared to placebo for patients with previously treated cholangiocarcinoma and which targetable mutation?**
  - IDH1
  - HER2
  - BRAF